Prognostic Factors Influencing the Survival of Patients with Metastatic Non-Small Cell Lung Cancer in the Moroccan Population: Retrospective Study of 405 Cases
Introduction: Non-small cell lung cancer is the most common lung cancer. Despite the
therapeutic advances, its prognosis is very reserved. Aim: Determine the different prognostic factors of patients
with metastatic non-small cell lung cancer and their correlation with patient
survival. Methods: A retrospective study was conducted at the medical oncology department
of Hassan II University Hospital in Fez, collecting 405 patients during a
period of 10 years, from January 2008 to January 2018. The statistical analysis
of the results was done by the software SPSS version 23, the survival was
calculated by the Kaplan-Meier method. The
Cox method was used to study prognostic factors. Results: The average age of our patients was 59 years, with a sex ratio M/F of 6.1. In multivariate analysis, we found a
significant correlation between the deterioration of survival and an age
greater than 75 years (p = 0.023), a general degraded state (p <
0.001), presence of a biological inflammatory syndrome (p < 0.001), anemia
(p < 0.001) and hypoalbuminemia (p < 0.001). In addition, no significant
association was found in patients with toxic habits
or multiple metastatic sites. Conclusion: The prognostic factors of metastatic NSCLC in our patients were PS, age, anemia, hypoalbuminemia and
inflammatory syndrome. We propose to validate all the factors identified by retrospective studies by prospective studies in
order to guarantee the best chances of survival for patients.
References
[1]
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. https://doi.org/10.3322/caac.21492
[2]
Karima, B. (2016) Le registre des cancers de la région du grand Casablanca pour la période 2008-2012. Edition 2016. Fondation Lalla Salma Prévention et Traitement des Cancers.
[3]
Mountain, C.F. (1997) Revisions in the International System for Staging Lung Cancer. Chest, 111, 1710-1717. https://doi.org/10.1378/chest.111.6.1710
[4]
Skarin, A.T., Herbst, R.S., Leong, T.L., Bailey, A. and Sugarbaker, D. (2001) Lung Cancer in Patients under Age 40. Lung Cancer, 32, 255-264.
https://doi.org/10.1016/S0169-5002(00)00233-6
[5]
Salloum, R.G., Smith, T.J., Jensen, G.A. and Lafata, J.E. (2012) Survival among Non- Small Cell Lung Cancer Patients with Poor Performance Status after First Line Chemotherapy. Lung Cancer, 77, 545-549.
https://doi.org/10.1016/j.lungcan.2012.04.019
[6]
Chermiti Ben Abdallal, F., Ben Ali, G., Sadok Boudaya, M., Mlika, M., Chtourou, A., Taktak, S. and Ben Kheder, A. (2014) Traitement et pronostic du cancer bronchique non à petites cellules au stade avancé. Revue des Maladies Respiratoires, 31, 214-220.
https://doi.org/10.1016/j.rmr.2013.09.002
[7]
Paesmans, M. (2008) Les facteurs pronostiques. Revue des Maladies Respiratoires, 25, 3S99-3S106. https://doi.org/10.1016/S0761-8425(08)82014-1
[8]
Nakamura, H., Ando, K., Shinmyo, T., Morita, K., Mochizuki, A., Kurimoto, N. and Tatsunami, S. (2011) Female Gender Is an Independent Prognostic Factor in Non- Small-Cell Lung Cancer: A Meta-Analysis. Annals of Thoracic and Cardiovascular Surgery, 17, 469-480. https://doi.org/10.5761/atcs.oa.10.01637
[9]
Albain, K.S., Crowley, J.J., LeBlanc, M. and Livingston, R.B. (1991) Survival Determinants in Extensive-Stage Non-Small-Cell Lung Cancer: The Southwest Oncology Group Experience. Journal of Clinical Oncology, 9, 1618-1626.
https://doi.org/10.1200/JCO.1991.9.9.1618
[10]
O’Connell, J.P., Kris, M.G., Gralla, R.J., Groshen, S., Trust, A., Fiore, J.J., Kelsen, D.P., Heelan, R.T. and Golbey, R.B. (1986) Frequency and Prognostic Importance of Pre-Treatment Clinical Characteristics in Patients with Advanced Non Small Cell Lung Cancer Treated with Combination Chemotherapy. Journal of Clinical Oncology, 4, 1604-1614. https://doi.org/10.1200/JCO.1986.4.11.1604
[11]
Yoshino, I., Kawano, D., Oba, T., Yamazaki, K., Kometani, T. and Maehara, Y. (2006) Smoking Status as a Prognostic Factor in Patients with Stage I Pulmonary Adenocarcinoma. The Annals of Thoracic Surgery, 81, 1189-1193.
https://doi.org/10.1016/j.athoracsur.2005.09.028
[12]
Nancy, L.G., Kursad, T. and Kimberly, H. (2009) Impact and Interactions between Smoking and Traditional Prognostic Factors in Lung Cancer Progression. Lung Cancer, 66, 386-392. https://doi.org/10.1016/j.lungcan.2009.02.012
[13]
Videtic, G.M.M., Stitt, L.W., Dar, A.R., Kocha, W.I., Tomiak, A.T., Truong, P.T., Vincent, M.D. and Yu, E.W. (2003) Continued Cigarette Smoking by Patients Receiving Concurrent Chemoradiotherapy for Limited-Stage Small-Cell Lung Cancer Is Associated with Decreased Survival. Journal of Clinical Oncology, 21, 1544-1549.
https://doi.org/10.1200/JCO.2003.10.089
[14]
Blanchon, F., Grivaux, M. and Collon, T. (2002) Epidemiologic of Primary Bronchial Carcinoma Management in the General French Hospital Centers. Revue des Maladies Respiratoires, 19, 727-734.
[15]
Wilde, J., Haenselt, V. and Luft, D. (1990) The Relationship of Histological Type and Tumor Location to Prognosis in 1000 Patients with Lung Resection with Special Reference to Adenocarcinoma. Pneumologie, 44, 1287-1293.
[16]
Capewell, S. and Sudlow, M.F. (1990) Performance and Prognosis in Patients with Lung Cancer. The Edinburgh Lung Cancer Group. Thorax, 45, 951-956.
[17]
Wakelee, H.A., Bernardo, P., Johnson, D.H. and Schiller, J.H. (2006) Changes in the Natural History of Non Small Cell Lung Cancer (NSCLC)—Comparison of Outcomes and Characteristics in Patients with Advanced NSCLC Entered in Eastern Cooperative Oncology Group Trials before and after 1990. Cancer, 106, 2208-2217.
https://doi.org/10.1002/cncr.21869
[18]
Caro, J.J., Salas, M., Ward, A. and Goss, G. (2001) Anemia as an Independent Prognostic Factor for Survival in Patients with Cancer: A Systemic, Quantitative Review. Cancer, 91, 2214-2221.
https://doi.org/10.1002/1097-0142(20010615)91:12<2214::AID-CNCR1251>3.0.CO;2-P
[19]
Takigawa, N., Segawa, Y., Okahara, M., Maeda, Y., Takata, I., Kataoka, M. and Fujii, M. (1996) Prognostic Factors for Patients with Advanced Non-Small Cell Lung Cancer: Univariate and Multivariate Analyses Including Recursive Partitioning and Amalgamation. Lung Cancer, 15, 67-77.
https://doi.org/10.1016/0169-5002(96)00571-5
[20]
Kasuga, I., Makino, S., Kiyokawa, H., Katoh, H., Ebihara, Y. and Ohyashiki, K. (2001) Tumor-Related Leukocytosis Is Linked with Poor Prognosis in Patients with Lung Carcinoma. Cancer, 92, 2399-2405.
https://doi.org/10.1002/1097-0142(20011101)92:9<2399::AID-CNCR1588>3.0.CO;2-W
[21]
Aoe, K., Hiraki, A., Ueoka, H., Kiura, K., Tabata, M., Tanaka, M. and Tanimoto, M. (2004) Thrombocytosis as a Useful Prognostic Indicator in Patients with Lung Cancer. Respiration, 71, 170-173. https://doi.org/10.1159/000076679
[22]
Shafiq, M. and Venkateshiah, S. (2011) Hematologic Abnormalities Associated with Lung Carcinoma. Respiratory Care, 56, 523-526.
https://doi.org/10.4187/respcare.00944
[23]
Petrelli, F., Cabiddu, M., Coinu, A., Borgonovo, K., Ghilardi, M., Lonati, V. and Barni, S. (2015) Prognostic Role of Lactate Dehydrogenase in Solid Tumors: A Systematic Review and Meta-Analysis of 76 Studies. Acta Oncologica, 54, 961-970.
https://doi.org/10.3109/0284186X.2015.1043026
[24]
Lee, D.S., Park, K.R., Kim, S.J., Chung, M.J., Lee, Y.H., Chang, J.H., Kang, J.H., Hong, S.H., Kim, M.S. and Kim, Y.S. (2016) Serum Lactate Dehydrogenase Levels at Presentation in Stage IV Non-Small Cell Lung Cancer: Predictive Value of Metastases and Relation of Survival Outcomes. Tumor Biology, 37, 619-625.
https://doi.org/10.1007/s13277-015-3776-5
[25]
Espinosa, E., Feliu, J., Zamora, P., Gonzalez Baron, M., Sanchez, J.J., Ordonez, A. and Espinosa, J. (1995) Serum Albumin and Other Prognostic Factors Related to Response and Survival in Patients with Advanced Non-Small Cell Lung Cancer. Lung Cancer, 12, 67-76. https://doi.org/10.1016/0169-5002(95)00407-R
[26]
Hara, M., Matsuzaki, Y., Shimuzu, T., Tomita, M., Ayabe, T., Enomoto, Y. and Onitsuka, T. (2007) Preoperative Serum C-reactive Protein Level in Non-Small Cell Lung Cancer. Anticancer Research, 27, 3001-3004.
[27]
Alifano, M., Falcoz, P.E., Seegers, V., Roche, N., Schussler, O., Younes, M., Antonacci, F., Forgez, P., Dechartres, A., Massard, G., Damotte, D. and Régnard, J.F. (2011) Preresection Serum C-Reactive Protein Measurement and Survival among Patients with Resectable Non-Small Cell Lung Cancer. The Journal of Thoracic and Cardiovascular Surgery, 142, 1161-1167.
[28]
Jing, X., Huang, C., Zhou, H., Li, C., Fan, L., Chen, J., Zhang, G., Liu, Y., Cui, Z., Qi, D. and Ma, J. (2015) Association between Serum C-Reactive Protein Value and Prognosis of Patients with Non-Small Cell Lung Cancer: A Meta-Analysis. International Journal of Clinical and Experimental Medicine, 8, 10633-10639.
[29]
Wao, H., Mhaskar, R., Kumar, A., Miladinovic, B. and Djulbegovic, B. (2013) Survival of Patients with Non-Small Cell Lung Cancer without Treatment: A Systematic Review and Meta-Analysis. Systematic Reviews, 2, Article No. 10.
https://doi.org/10.1186/2046-4053-2-10
[30]
Baggstrom, M.Q., Stinchcombe, T.E. and Fried, D.B. (2007) Third-Generation Chemotherapy Agents in the Treatment of Advanced Non-Small Cell Lung Cancer: A Meta-Analysis. Journal of Thoracic Oncology, 2, 845-853.
https://doi.org/10.1097/JTO.0b013e31814617a2
